MannKind | MNKD - Operating Profit

Stock Price
5.90
Daily Change
-0.31 -4.98%
Monthly
5.00%
Yearly
4.63%
Q1 Forecast
5.60

MannKind reported $-41.05M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
Adma Biologics USD 51.01M 8.21M Sep/2025
Dynavax Technologies USD 21.27M 10.41M Sep/2025
Eli Lilly USD 8.39B 1.37B Sep/2025
Halozyme Therapeutics USD 217.92M 15.48M Sep/2025
Insmed USD -261.35M 7.48M Sep/2025
MacroGenics USD 18.64M 55.4M Sep/2025
MannKind USD -41.05M 2.36M Sep/2025
Merck USD 6.24B 318M Dec/2025
Novo Nordisk DKK 5.18B 33.61B Jun/2025
Pfizer USD 4.65B 3.99B Dec/2025
Sanofi EUR 1.7B 2.17B Dec/2025
Xencor USD -47.52M 14.35M Sep/2025